SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its listing on Bifinance and the upcoming release of a mobile app. Discussions highlight the coin's resilience, community-driven development, and potential for significant growth. The community emphasizes its unique approach and grind, attracting attention within the Solana meme coin space.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as its AI initiatives gain traction, including a major customer win for its AI chips, signaling growing domestic demand and a potential shift away from reliance on US tech. Community members are discussing price targets, Cathie Wood's renewed interest, and the potential impact of geopolitical factors on the stock. Some traders anticipate a continued rally, while others suggest caution due to overbought conditions and potential government actions.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates the release of GDP data provided by Pyth. There is also speculation about potential allocations from other projects, like $DJT, with some users suggesting connections to other trending coins. The community is also actively discussing potential price movements and future adoption.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail traders eye further gains, drawing comparisons to Nvidia and Google's YTD performance. Community discussion revolves around the momentum in quantum computing, with some highlighting the company's partnerships and others questioning its valuation relative to revenue. Recent news of government contracts may be contributing to the bullish sentiment.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as traders discuss potential entry points and whether it's time to 'buy the dip.' Community members are also comparing PEPE to other meme coins, particularly other '4chan frogs' like HONK.X, speculating on which will see the most gains. Some traders also suggest that altcoins and meme coins with real world utility are better long term investments.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as investors await earnings, with the community actively discussing potential price target increases from analysts. Optimism surrounds Micron's positioning in the AI sector, while some traders express caution, citing the stock's recent run-up and potential for profit-taking. The broader semiconductor sector is being closely watched in relation to Micron's performance.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid excitement around potential benefits from Nvidia's AI initiatives and a possible hyperscaler deal, fueling speculation of a short squeeze given the high short interest. The community is actively discussing the company's data center infrastructure and its strategic positioning within the AI sector, as well as potential price targets and the likelihood of an upcoming offering. Chatter about a potential bidding war for the company is also circulating.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

FIRECOIN.X is trending as community members signal their conviction with repeated "I am IN" declarations and calls to "BUY." The enthusiasm suggests many believe FIRECOIN.X is primed for a substantial move, potentially outperforming other tokens on the Solana blockchain.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK.X is trending as a satirical take on traditional retirement plans, with the community rallying around its narrative as a path to early retirement. Many express strong bullish sentiment, citing the project's rapid growth and community-driven approach within the Solana memecoin space. The coin is being positioned as a way to mock the system that has failed many, offering an alternative path to financial freedom.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as it moves closer to merging with Infleqtion, a quantum computing company. Community chatter highlights Infleqtion's existing revenue and partnerships, including ties with NVIDIA, fueling speculation that $CCCX is undervalued compared to its peers in the quantum computing space like $IONQ and $RGTI. Some investors are also closely watching the warrants ($CCCXW), interpreting their activity as a bullish signal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly and Company (LLY) announced on Tuesday that it plans to construct a new $ 6.5 billion manufacturing facility in Texas as part of its efforts to expand domestic medicine production.The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lilly-plans-to-build-a-new-6-5-billion-facility-to-manufacture-active-pharmaceutical-ingredients-in-texas-302563621.html">stated</a> that the Houston facility will be operational within five years and will focus on manufacturing the company's pipeline of small molecule medicines across various therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. The company also said that the site will be among those that manufacture its much-awaited oral obesity drug Orforglipron. Lilly expects to make regulatory submissions for Orforglipron in the treatment of obesity by the end of this year."Our new Houston site will enhance Lilly's ability to manufacture Orforglipron at scale and, if approved, help fulfill the medicine's potential as a metabolic health treatment for tens of millions of people worldwide who prefer the ease of a pill that can be taken without food and water restrictions," said CEO David A Ricks.According to Lilly, the new facility will bring 615 new high-wage jobs to the Greater Houston area, including engineers, scientists, and lab technicians, in addition to 4,000 construction jobs. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory while message volume fell from ‘normal’ to ‘low’ levels.In February, Lilly announced its plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the U.S., bringing the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.While three of the facilities will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis, and further strengthening Lilly's supply chain, the fourth will extend the company's global parenteral manufacturing network for future injectable therapies, the company had said.Last week, the company also <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">announced</a> plans for a $5 billion manufacturing facility in Virginia.LLY stock is down 3% this year and approximately 19% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ionis-pharma-stock-rises-after-multiple-price-target-hikes/chDLGmZR35v">Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas

The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.

Equity

The new facility, located at Generation Park in Houston, marks the second of four new U.S. sites that Lilly intends to announce this year.


Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

KalVista Pharmaceuticals (KALV) announced on Friday that the European Commission (EC) and the Swiss Agency for Therapeutic Products, Swissmedic, have approved its Ekterly for the symptomatic treatment of acute attacks of hereditary angioedema (HAE).Ekterly was approved by both agencies for the treatment of adults and adolescents aged 12 years and older with HAE. It is the first and only oral on-demand treatment for HAE in the two regions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-european-commission-and">said</a>.Shares of the company traded lower by 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALV">KalVista</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_12_33_07_PM_png_055493ce17.webp" alt="KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock rallying to $22 in 12 months.<stembedurl>https://stocktwits.com/PokerMunkee/message/629305223</stembedurl>Another opined that the stock has a lot of “potential and great setup.”<stembedurl>https://stocktwits.com/Shakattack31/message/629258146</stembedurl>“With our U.S. launch progressing well and approvals now secured in the U.K., EU, and Switzerland, we look forward to bringing this innovation to more people living with HAE, beginning with our first European launch in Germany,” CEO Ben Palleiko said. The company expects to launch Ekterly in Germany in the fourth quarter and in Switzerland in the second half of 2026.The recent approvals are based on the results of a late-stage trial where Ekterly achieved significantly faster symptom relief, reduction in attack severity, and attack resolution than placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.The EC approval applies to all 27 EU member states as well as Iceland, Liechtenstein, and Norway. In August, the European Medicines Agency also granted Ekterly 10 years of market exclusivity.Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Ekterly <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">received</a> approval from the U.S. Food and Drug Administration for the treatment of HAE in July.KALV stock is up by about 61% this year and by about 24% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/emergent-biosolutions-stock-rises-after-receiving-fresh-international-purchase-orders/chD3729R3Tf">Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

Ekterly is now the first and only oral on-demand treatment for hereditary angioedema in the two regions, the company said. 

Ride-hailing platform Uber Technologies (UBER) announced on Thursday that it has entered into a strategic partnership with drone delivery provider Flytrex Inc.Drone delivery services are expected to begin with Uber Eats pilot markets in the U.S. by the end of the year, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.uber.com/news-events/news/press-release-details/2025/Uber-Partners-with-Flytrex-to-Launch-Drone-Delivery/default.aspx">said</a>. The partnership is part of the company’s efforts to build a delivery network that extends beyond traditional modes of transport, such as cars and bikes. The company already has sidewalk robots in its network and is seeking to expand its network further with autonomous aerial delivery.<a href="https://stocktwits.com/symbol/UBER">Shares of Uber</a> traded 2% higher at the time of writing. On Stocktwits, retail sentiment around UBER fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_10_08_01_AM_png_8398df886d.webp" alt="UBER's Sentiment Meter and Message Volume as of 10:08 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="576" height="62"><figcaption>UBER's Sentiment Meter and Message Volume as of 10:08 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism on the stock, saying it’s “going higher for longer.”<stembedurl>https://stocktwits.com/trading__analysis/message/629113251</stembedurl>Another user believes the partnership is a “great move.”<stembedurl>https://stocktwits.com/RunGal/message/629113752</stembedurl>Uber noted on Thursday that Flytrex is one of only four drone delivery providers authorized by the Federal Aviation Administration (FAA) for beyond visual line of sight operations. The firm highlighted that it is making its first investment in drone technology with Flytrex to accelerate the development and deployment of drone delivery technology.According to Uber, Flytrex has completed over 200,000 deliveries across the U.S. Flytrex currently operates in North Carolina, Texas, and other approved locations. The company typically serves customers within a two- to three-mile radius of its fulfillment centers, and its drones can reach speeds of up to 32 km/h.Uber stock is up 57% this year and approximately 29% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-announces-1-for-250-reverse-stock-split/chDcxioR3b7">Bollinger Innovations Announces 1-For-250 Reverse Stock Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Uber car is seen on the street in Krakow, Poland, on March 6, 2025. (Photo by Klaudia Radecka/NurPhoto via Getty Images)

Uber Inks Partnership With Flytrex For Drone Delivery In US: Retail Sees Stock ‘Going Higher For Longer’

The company stated that drone delivery services are expected to begin with Uber Eats pilot markets in the U.S. by the end of the year.

Shares of Roivant (ROIV) jumped 9% on Wednesday after the company, along with Priovant Therapeutics, announced positive results from a late-stage trial evaluating Brepocitinib in dermatomyositis.Dermatomyositis is a multi-organ idiopathic inflammatory condition that affects approximately 50,000 adults in the U.S. and is characterized by debilitating muscle weakness and skin lesions. No targeted therapies are approved for the condition, and a majority of patients are treated with high-dose oral steroids.Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, including measurements of skin disease, muscle disease, steroid-sparing effect, and rapidity of onset, the company said.On Stocktwits, retail sentiment around ROIV stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:619/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_2_05_09_PM_png_94ffd6f84d.webp" alt="ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="619" height="61"><figcaption>ROIV's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism that the stock would rally further to $17.<stembedurl>https://stocktwits.com/StockBraker/message/628947861</stembedurl>Another user also cheered the stock’s rally over the past few weeks.<stembedurl>https://stocktwits.com/bbbloo/message/628950392</stembedurl>The company stated that 30mg of Brepocitinib achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo. It added that more than two-thirds of patients receiving the Brepocitinib 30 mg dose experienced at least a moderate response, with a TIS equal to or greater than 40, and nearly half experienced a major response, with a TIS equal to or exceeding 60.Furthermore, 42% of Brepocitinib 30 mg patients were able to discontinue steroids altogether, compared to 23% for the placebo, while 62% achieved a steroid dose of 2.5 mg or less per day. The safety profile observed in the study was consistent with that of previous trials, the company stated.The company plans to file for approval of the drug with the U.S. Food and Drug Administration for the treatment of dermatomyositis in the first half of 2026.ROIV stock is up 31% this year and approximately 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-in-talks-to-renew-jv-with-chinas-saic-report/chDGDTkRd6t">GM In Talks To Renew JV With China’s SAIC: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said. 

Duolingo (DUOL) shares were down nearly 4% in early trading on Wednesday, becoming the top trending ticker on Stocktwits after Citigroup lowered its price target on the stock to $375 from $400.Citigroup maintained a ‘Buy’ rating after attending the company’s annual global event Duocon 2025, according to TheFly. The firm believes that Duolingo's product announcements this year had a lower profile compared to past years.On Tuesday, Duolingo announced two major product updates at Duocon, primarily related to an integration that brings the Duolingo Score to LinkedIn Profiles, and the expansion of its Duolingo Chess course with an Android launch and a new player-versus-player mode on iOS.Retail sentiment on <a href="https://stocktwits.com/symbol/DUOL">Duolingo</a> improved to ‘bullish’ from ‘neutral’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:797/102;" src="https://news.stocktwits-cdn.com/DUOL_sentiment_png_d242d7e2c6.webp" alt="DUOL sentiment.png" width="797" height="102"><figcaption>DUOL sentiment and message volume September 17, 2025, as of 10:15 am ET | Source: Stocktwits</figcaption></figure>A user on Stocktwits noted that they were considering accumulating Duolingo stock.<stembedurl>https://stocktwits.com/ChrisChristopherson/message/628956384</stembedurl>Citigroup stated that the company continues to enhance its platform, which should help drive engagement; however, the firm has reduced its Duolingo user forecasts to reflect trends in third-party apps.In August, Duolingo beat its second-quarter results and raised its annual forecasts, driven by an increase in daily active users on the app.Separately, media reports noted that Hungary’s competition authority was investigating Duolingo regarding misleading claims about the effectiveness of its platform.Another user on Stocktwits noted that the stock was in a “great spot to buy.”&nbsp;Shares of Duolingo have declined over 16% this year but have gained 8% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-rejigs-ai-assistant-for-online-sellers-report/chDGpY8Rd6L">Amazon Rejigs AI Assistant For Online Sellers: Report</a>

A laptop keyboard and Duolingo on App Store displayed on a phone screen are seen in this illustration photo. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event

Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past.

Eli Lilly and Company (LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility in Virginia as it seeks to expand domestic medicine production.The new facility will be located west of Richmond in Goochland County and will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune diseases, and other advanced therapies. The company also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-announces-plans-build-5-billion-manufacturing-facility">said</a> that the new site will boost its domestic manufacturing of antibody-drug conjugates, a targeted therapy designed to deliver medicines directly to diseased cells.The facility is expected to be completed within the next five years, creating 2,450 high-wage manufacturing and construction jobs. This includes 650 high-paying jobs, including engineers, scientists, operations personnel, and lab technicians, in addition to 1,800 construction jobs.The company also stated that it intends to announce three additional U.S. manufacturing sites this year and to begin producing medicines at these four facilities within five years.Shares of LLY traded nearly 2% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at 'low' levels.In February, Lilly announced its plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the U.S., bringing the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.While three of the facilities will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis, and further strengthening Lilly's supply chain, the fourth will extend the company's global parenteral manufacturing network for future injectable therapies, the company had said.The facility in Virginia is the first to be announced among the four facilities.Pharma companies have been boosting U.S. investment under pressure from the Trump administration. Last month, Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">said</a> that he would initially impose small tariffs on pharma imports, which would eventually reach 250%.LLY stock is down 1% this year and approximately 18% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-says-new-obesity-treatment-achieved-11.8-percent-body-weight-reduction-in-late-stage-study/chwymJURdz1">Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside

The company also said that it intends to announce three other U.S. manufacturing sites this year. 

A pedestrian walks past the American fashion brand Ralph Lauren store in Hong Kong.

Ralph Lauren Unveils Three-Year Outlook – Here Are The Key Points

Ralph Lauren expects operating margin to expand by approximately 100 to 150 basis points by fiscal 2028, while capital expenditures are expected to represent about 4% to 5% of revenue annually over the next three years.

Dave &amp; Buster's Entertainment (PLAY) was among the top five losers on Stocktwits after multiple price target cuts from Wall Street following its second-quarter sales, which were pressured due to a difficult macro environment and challenges related to the brand.Shares of the company were down nearly 17% before the bell on Tuesday after Dave &amp; Buster’s <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dave-and-busters-stock-plunging-premarket/chwyaxsRdyl">missed quarterly results</a>. UBS cut its price target on Dave &amp; Buster's to $25 from $29 and maintained a ‘Neutral’ rating, according to TheFly.The firm said that <a href="https://stocktwits.com/symbol/PLAY">Dave &amp; Buster's</a> second-quarter results included still pressured sales trends, likely given a difficult macro and brand-specific challenges, while margins and earnings were also depressed.UBS noted that while the company is still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.The retail user message count on the stock jumped 5,200% in the last 24 hours on Stocktwits. Retail sentiment remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:792/102;" src="https://news.stocktwits-cdn.com/PLAY_sentiment_png_f0791affdf.webp" alt="PLAY sentiment.png" width="792" height="102"><figcaption>PLAY sentiment and message volume September 16, 2025, as of 8:10 am ET | Source: Stocktwits</figcaption></figure>Truist Securities cut its price target on Dave &amp; Buster's to $22 from $27 and maintained a ‘Hold’ rating. The firm said that the company's same-store sales decelerated in the back half of the quarter despite much easier year-ago compares as growing macro headwinds offset recent gains from its "back to basics" approach.Brokerage Truist Securities noted that while it sees incremental sales drivers in the second half of 2025, it also sees a risk that consumer pressures mount. Piper Sandler lowered its price target on Dave &amp; Buster's to $26 from $30 and maintained a ‘Neutral’ rating, according to TheFly.A bearish user on Stocktwits noted that there was “no upward catalyst” until the next earnings.<stembedurl>https://stocktwits.com/Bobky2030/message/628801944</stembedurl>Shares of Dave &amp; Buster’s have declined over 17% this year and lost nearly a quarter of its value in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/united-airlines-to-hire-2500-employees-at-newark-airport/chwyLDMRdzb">United Airlines To Hire 2,500 Employees At Newark Airport</a>

The exterior of a Dave & Buster's restaurant is seen on June 10, 2025 in Austin, Texas.

Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot

UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store sales represents potential upside for shares.

Telsey Advisory Group maintained a ‘Less Risk’ rating on Caleres (CAL) after its quarterly results, stating that even as the broader footwear market remained challenged in the second quarter, the company was able to gain market share in several segments, like women's fashion and shoe chains.&nbsp;Dana Telsey of Telsey Advisory Group noted that tariffs weighed on the second quarter's margin and are expected to continue impacting the rest of the year. She added that sales declined due to continued pressure on value-priced brands and order cancellations linked to manufacturing in China.&nbsp;Retail sentiment on <a href="https://stocktwits.com/symbol/CAL">Caleres</a> remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits. The retail user message count on the stock increased by 700% on Stocktwits over the last 24 hours, as of Friday morning.<figure class="image"><img style="aspect-ratio:816/105;" src="https://news.stocktwits-cdn.com/CAL_sentiment_png_117220490f.webp" alt="CAL sentiment.png" width="816" height="105"><figcaption>CAL sentiment and message volume September 5, 2025, as of 12:30 pm ET | Source: Stocktwits</figcaption></figure>Caleres reported second-quarter net sales of $658.5 million, compared with estimates of $656.5 million, according to data from Fiscal AI. Its adjusted earnings per share of $0.35 missed expectations of $0.56. Shares of the company were up 10% during midday trading on Friday.The brokerage noted that the continued suspension of annual guidance speaks to the challenging operating environment and makes visibility to the earnings potential in the shorter term more challenging.&nbsp;Caleres acquired Stuart Weitzman from Tapestry for $120.2 million, aiming to add a storied name in luxury footwear to its diverse brand portfolio.&nbsp;“The acquisition of Stuart Weitzman brings a quality brand name to the Brand Portfolio business that can add to the topline and future profitability potential, and we believe the brand can benefit from a true footwear pure-play owner,” Dana Telsey added.Caleres' shares have lost over 32% of their value this year and declined nearly 60% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/safe-and-green-s-olenox-hits-3-000-barrel-milestone-post-texas-acquisition-retail-chatter-surges-850/chwI0VNRdqO">Safe &amp; Green’s Olenox Hits 3,000-Barrel Milestone Post-Texas Acquisition, Retail Chatter Surges 850%</a>

 In this photo illustration, the Caleres Footwear company logo seen displayed on a smartphone.

Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700%

Caleres reported second-quarter net sales of $658.5 million, compared with estimates of $656.5 million, according to data from Fiscal AI.

Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$154.75
Prev Close	$152.28
Open	$150.35
Dividend Yield	N/A
50-Day Moving Average	$164.18
Beta	N/A
Avg. Volume	46,994.24
PE Ratio	N/A

52-Week High	$179.56
52-Week Low	$134.72
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VFMO
Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VFMO News

VFMO Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF